During the 2015 Ebola pandemic, 1,000 people were dying every month. Manufacturing 3,000 doses of the ZMapp experimental drug would have required 40,000 m² of greenhouse and taken 90 days.
BUT WHAT IF WE DARE TO…
…BE BOLD
…DEFY THE STATUS QUO
…ASPIRE TO PRODUCE THESE DOSES IN 24 HOURS
Born from our dream to produce enough Ebola drug quickly,
LenioBio has ONE GOAL.

To simplify manufacturing and speed up delivering drugs to the patient.
Today, LenioBio is driven by this passion: Our determination to turn a specific manufacturing challenge into hopefully a solution for the whole industry.
A strong foundation
All our activities are driven by our core values.
Fearless in our commitment.
Some dream of success, whereas we get up every morning to make it happen.
Respect is in our DNA.
Respect guides all our interactions. Be your authentic self, we like it that way.
Only united can we excel.
Continuous improvement is a shared responsibility.
Simply caring for the better.
Actively listen and be emotionally present, connect with dignity and respond with compassion.
Driven to learn, grow and progress.
Revolution comes with risks; we can only grow by continuously learning from our mistakes.
LenioBio announces the successful scaling of the ALiCE lysate manufacture and cell-free protein synthesis reaction – a world first for eukaryotic cell-free expression.
In February 2022, LenioBio completes the Horizon 2020 PEPPER project on time – one of the few recipients of this prestigious grant to do so.
In November 2021, led by the Bridford Group, LenioBio closes its Series A extension round amounting to 11.5 M. €. Along with the funding round, long-term experts in pharma manufacturing and life sciences joined our Board.
Surrounded by the employees, investors and business partners, LenioBio celebrated its 5th anniversary on September 2021.
Find out more about the event on our Press Release.
LenioBio is awarded the Eurostars grant in June 2021, leading a consortium with two European partners, Wageningen University, The Netherlands, and EnginZyme AB, Sweden. The project goal is to develop the first high-throughput glycoprotein production and manufacturing system, based on the ALiCE® technology.
Continuous research and development allow LenioBio to produce our first batch of 10-liter lysate
in September 2021, which is another 10- fold scaling and a major milestone for the company.
Our focus on accelerating the scaling of the ALiCE technology bears its first fruits by end of 2020. LenioBio achieves the first scaling step to 1 liter lysate production.
In February 2020, LenioBio and Fraunhofer IME are awarded a grant by the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung – BMBF) that supports innovative projects and ideas in research through targeted funding programs. In this project (ThinkBIG) both partners conduct fundamental research to scale the cell-free technology to 1 and 10 liter lysate production.
In December 2019, LenioBio is awarded the prestigious Horizon 2020 grant by the European Innovation Council to support our accelerated growth. The ambitious project goal is to build a pilot line for large scale manufacturing of the ALiCE system and to optimize the technology.
LenioBio concludes the Series A funding round in September 2019, securing the first investment from external investors with a volume of 4 M. €.
After the successful launch of our first kit, we focus on accelerating the scaling of the technology, improve further the productivity and robustness, allowing any potential customer lacking cell-fermentation infrastructure to produce clinical trial material.
In March 2019, LenioBio signs a distribution agreement with Merck Millipore Sigma to distribute the ALiCE kit worldwide.
More information about ALiCE distribution and purchase options on our online shop.
The ALiCE kit is launched as an expression kit for research and pre-clinical development. The eukaryotic cell-free kit offers our customers the highest protein yields in a single step than any other cell-free expression system currently on the market.
In February 2018, LenioBio acquires the exclusive license from Corteva Agriscience™ (former Dow AgroSciences) to further develop and commercialize the technology across all industries.
Find out more about this agreement.
Born from his dream to produce enough Ebola vaccine quickly for those in urgent need, Dr. Remberto Martis founds LenioBio GmbH in September 2016.
Together with a Business Angel, the foundation of LenioBio is set and an ambitious growth strategy to develop and scale the BYL technology is implemented.
The ALiCE technology has been developed by the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and has been further optimized in the consorted efforts of the Fraunhofer IME and Corteva Agriscience™ (former Dow AgroSciences) to provide an efficient and high-yielding plant-based, cell-free production system for the internal crop development of Corteva Agriscience™ (former Dow AgroSciences).
This technology, named BYL (BY-2 Lysate), was kept as an industry secret and can only be tracked to one small publication in 2015.
The current procedure is largely described in the published patents, which are the basis for the license deals with Fraunhofer IME and Corteva Agriscience™ (former Dow AgroSciences).
